Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Volunteers Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136
View directory record Official record
Conditions
No Evidence of Disease
Interventions
UV Light Therapy, Placebo, Celecoxib, Biopsy, Imaging Biomarker Analysis
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Kale Consumption on Human Xenobiotic Metabolizing Enzymes

NCT03449849
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Base Diet, Kale Treatment
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

NCT05789745
View directory record Official record
Conditions
Volunteers, Healthy
Interventions
Recombinant human plasma gelsolin, placebo
Drug · Other
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly

NCT00333528
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Human butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

NCT00415051
View directory record Official record
Conditions
Rift Valley Fever
Interventions
RVF MP-12
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

NCT00333515
View directory record Official record
Conditions
Healthy Volunteers, Chemical Terrorism, Chemical Warfare
Interventions
Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 25, 2026, 9:08 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
CMND-100
Drug
Lead sponsor
Clearmind Medicine Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Testing the AVI-7100 Flu Drug in Healthy Volunteers

NCT01747148
View directory record Official record
Conditions
Influenza
Interventions
AVI-7100 versus placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

NCT05387083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Low Dose TP-05, High Dose TP-05, Placebo Comparator
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

NCT02766621
View directory record Official record
Conditions
Healthy
Interventions
PF-06823859, Placebo injection SC/IV
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 25, 2026, 9:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

NCT07043634
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
Combination Product
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Exploring the Effects of Corticosteroids on the Human Hippocampus

NCT03896659
View directory record Official record
Conditions
Hydrocortisone, Depression, Healthy Volunteers
Interventions
Hydrocortisone Oral, Placebo Oral Tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

NCT02922946
View directory record Official record
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

NCT02562872
View directory record Official record
Conditions
Healthy
Interventions
DSM265, Placebo, Sporozoites, Infective mosquito bite
Drug · Biological
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

NCT01258530
View directory record Official record
Conditions
Influenza, Human
Interventions
over-encapsulated oseltamivir, oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 25, 2026, 9:08 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of VIS410 to Assess Safety and Pharmacokinetics

NCT02045472
View directory record Official record
Conditions
Influenza
Interventions
VIS410, Placebo
Drug
Lead sponsor
Visterra, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Sep 25, 2026, 9:08 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

NCT00938301
View directory record Official record
Conditions
Bipolar Depression
Interventions
PF-04455242, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Sep 25, 2026, 9:08 AM EDT